Date: 2012-08-21
Type of information: Clinical research agreement
Compound: non-invasive blood tests for early detection and prognosis of colorectal cancer
Company: VolitionRX (Singapore) Belgian Volition (Belgium) CHU UCL Mont-Godinne Hospital (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism:
Disease: colorectal cancer
Details: VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, has announced that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium. This is the fourth large-scale external clinical trial for VolitionRX. The trial will begin in early September, and is scheduled for completion next year. The trial will be a prospective longitudinal study including approximately 250 patients as they progress through diagnosis and treatment. The project aims to develop and clinically evaluate non-invasive blood tests for early detection and prognosis of colorectal cancer.
Financial terms:
Latest news:
